 |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Merck KGaA and Jerini Announce Collaboration to Develop Small Molecule Cancer Drugs29 Jan 2004 - Merck KGaA and Jerini AG announced a collaboration agreement to jointly develop small molecule inhibitors against an undisclosed target for oncology.Prior to the agreement, Jerini identified novel proprietary small molecule lead series by applying its Peptides-to-Drugs (P2D) approach. Merck and Jerini are joining forces to further develop Jerini's compounds. Initiation of pre-clinical development is planned for 2005. Under terms of the agreement, Jerini will receive an upfront payment, personnel funding, milestone payments, and royalties. Merck obtains worldwide rights for all indications in cancer, cardiovascular diseases, diabetes and thyroid disorders. Jerini could receive in excess of EUR 50 million if the product is approved. Further financial details were not disclosed. News regarding Research |
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
 Top |
|||
Contact
Print version
PDF version
Send article
RSS feed